Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 3, 2010, Pages

  Lee, Chen Hsiang ^a   Su, Lin Hui ^a   Lin, Wei Che ^a   Tang, Yang Fang ^a   Liu, Jien Wei ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Ertapenem; Extended spectrum lactamase; Osteomyelitis; Treatment failure

Indexed keywords

BACTERIAL ENZYME; BETA LACTAMASE CTX M; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; CTX M 14 ENZYME; ERTAPENEM; IMIPENEM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CULTURE; BONE BIOPSY; CASE REPORT; ESCHERICHIA COLI; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUMBAR VERTEBRA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SPONDYLITIS; URINARY TRACT INFECTION; URINE CULTURE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OSTEOMYELITIS; SPINAL DISEASES; TREATMENT FAILURE; URINARY TRACT INFECTIONS;

EID: 77957342311     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.06.023     Document Type: Article

References (21)

1. Paterson D.L., Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
2. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004, 48:1-14.
3. Livermore D.M., Sefton A.M., Scott G.M. Properties and potential of ertapenem. J Antimicrob Chemother 2003, 52:331-344.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Document M100-S16. Villanova, PA: CLSI; 2006.
5. National Committee for Clinical Laboratory Standards. Zone diameter interpretive standards and equivalent minimal inhibitory concentration (MIC) breakpoints for Enterobacteriaceae. Document M2-A7. Villanova, PA: NCCLS; 2002.
6. Farmer J.J. Enterobacteriaceae. Manual of clinical microbiology 2003, 636-653. ASM Press, Washington DC. 8th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (Eds.).
7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing-thirteenth informational supplement. Document M100-S13. Wayne, PA: NCCLS; 2003.
8. Lee C.H., Chu C., Liu J.W., Chen Y.S., Chiu C.J., Su L.H. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 β-lactamases. J Antimicrob Chemother 2007, 60:410-413.
9. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33:2233-2239.
10. Sapico F.L., Montgomerie J.Z. Pyogenic vertebral osteomyelitis: report of nine cases and review of the literature. Rev Infect Dis 1979, 1:754-776.
11. Kiffer C.R., Kuti J.L., Eagye K.J., Mendes C., Nicolau D.P. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp from Brazil. Int J Antimicrob Agents 2006, 28:340-344.
12. Teng C.P., Chen H.H., Chan J., Lye D.C. Ertapenem for the treatment of extended-spectrum β-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents 2007, 30:356-359.
13. Lew D.P., Waldvogel F.A. Osteomyelitis. Lancet 2004, 364:369-379.
14. Zimmerli W., Lew D.P., Waldvogel F.A. Pathogenesis of foreign body infection-evidence for a local granulocyte defect. J Clin Invest 1984, 73:1191-1200.
15. Ciampolini J., Harding K.G. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?. Postgrad Med J 2000, 76:479-483.
16. Herrmann M., Vaudaux P.E., Pittet D., Auckenthaler R., Lew P.D., Schumacher-Perdreau F., et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J Infect Dis 1988, 158:693-701.
17. Mader J.T., Shirtliff M.E., Bergquist S.C., Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res 1999, 360:47-65.
18. MacGregor R.R., Gentry L.O. Imipenem/cilastatin in the treatment of osteomyelitis. Am J Med 1985, 78:100-103.
19. Hsu H.L., Lu C.Y., Tseng H.Y., Lee P.I., Lai H.P., Lin W.C., et al. Empirical monotherapy with meropenem in serious bacterial infections in children. J Microbiol Immunol Infect 2001, 34:275-280.
20. Boselli E., Breilh D., Djabarouti S., Bel J.C., Saux M.C., Allaouchiche B. Diffusion of ertapenem into bone and synovial tissues. J Antimicrob Chemother 2007, 60:893-896.
21. Shah P.M., Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003, 52:538-542.